Avalyn Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-85.2	-49.74
Depreciation & Amortization	0.04	0.08
Loss (Gain) From Sale of Assets	-	0.05
Loss (Gain) From Sale of Investments	-2.35	-2.58
Stock-Based Compensation	3.27	2.47
Other Operating Activities	0.15	-
Change in Accounts Payable	1.4	0.23
Change in Other Net Operating Assets	1.22	1.13
Operating Cash Flow	-81.48	-48.37
Capital Expenditures	-0.34	-0.1
Investment in Securities	10.4	-91.38
Investing Cash Flow	10.06	-91.47
Issuance of Common Stock	0.02	0.05
Other Financing Activities	-0.59	-
Financing Cash Flow	99.79	0.09
Net Cash Flow	28.36	-139.75
Free Cash Flow	-81.83	-48.46
Free Cash Flow Per Share	-4.38	-9.32
Levered Free Cash Flow	-50.58	-
Unlevered Free Cash Flow	-50.58	-
Change in Working Capital	2.61	1.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q